Allogene Therapeutics

Allogene Therapeutics: Series E Funding Round

Allogene Therapeutics has successfully raised $325M in Series E funding, reaching a valuation of $3.9B.

Company Overview

Allogeneic CAR T therapy developer

Funding Details

The Series E round was led by TPG, with participation from Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.

Company Information

• Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080
• Founded: 2017
• Employees: 700+
• Category: Biotech

Investment

Allogene Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• TPG: Verified investor in Series E
• Gilead Sciences: Verified investor in Series E
• Pfizer: Verified investor in Series E
• Frazier Healthcare Partners: Verified investor in Series E
• University of California: Verified investor in Series E